Syndax Pharmaceuticals, Inc. Temporary Equity, Dividends, Adjustment
Syndax Pharmaceuticals, Inc. (SNDX) reported Temporary Equity, Dividends, Adjustment of $2.60 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-07.
Discontinued › Expense Statement › Operating Expenses
us-gaap:TemporaryEquityDividendsAdjustment · last filed 2019-03-07
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for the quarter ending 2016-09-30 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for the quarter ending 2016-06-30 was $0.00, a 100.00% decline year-over-year.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for the quarter ending 2016-03-31 was $2.60M, a 48.54% increase year-over-year.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for fiscal 2016 was $2.60M, a 74.05% decline from fiscal 2015.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for fiscal 2015 was $10.01M, a 53.33% increase from fiscal 2014.
- Syndax Pharmaceuticals, Inc. temporary equity, dividends, adjustment for fiscal 2014 was $6.53M.
| Period end | Temporary Equity, Dividends, Adjustment 3 month | Temporary Equity, Dividends, Adjustment 6 month | Temporary Equity, Dividends, Adjustment 9 month | Temporary Equity, Dividends, Adjustment 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $0.00 derived: sum of 2 quarters · filed 2019-03-07 | $0.00 derived: sum of 3 quarters · filed 2019-03-07 | $2.60M 10-K · filed 2019-03-07 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $2.60M 10-Q · filed 2017-11-08 | $6.11M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $2.60M 10-Q · filed 2017-08-10 | $6.11M derived: sum of 3 quarters · filed 2018-03-08 | $8.93M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-03-31 | $2.60M 10-Q · filed 2017-05-09 | $6.11M derived: sum of 2 quarters · filed 2018-03-08 | $8.93M derived: sum of 3 quarters · filed 2018-03-08 | $10.86M derived: sum of 4 quarters · filed 2018-03-08 |
| 2015-12-31 | $3.52M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $6.33M derived: sum of 2 quarters · filed 2018-03-08 | $8.26M derived: sum of 3 quarters · filed 2018-03-08 | $10.01M 10-K · filed 2018-03-08 |
| 2015-09-30 | $2.82M 10-Q · filed 2016-11-14 | $4.75M derived: sum of 2 quarters · filed 2016-11-14 | $6.50M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $1.93M 10-Q · filed 2016-08-15 | $3.68M 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $1.75M 10-Q · filed 2016-05-16 | |||
| 2014-12-31 | $6.53M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |